Professor Charles Mgone, Executive Director of EDCTP, said, "The TB and HIV co-epidemic is devastating, requiring a concerted global response. EDCTP in partnership with Aeras, Oxford-Emergent Tuberculosis Consortium and others is committed to accelerate research and development of this promising vaccine against tuberculosis by co-financing the clinical trial as an essential part in its evaluation."
Tuberculosis kills 1.7 million people per year, and more than two billion people worldwide are infected with TB approximately one out of every three people on the planet. People infected with HIV living in countries with high TB prevalence are 20 times more likely to develop TB than those who are HIV-negative. In 2008, there were an estimated 1.4 million new cases of TB among persons with HIV infection, and TB accounted for 23 percent of AIDS-related deaths, according to the World Health Organization (WHO). The Bacille Calmette-Gurin (BCG) vaccine, the only currently-licensed vaccine against TB, is not effective in preventing adult pulmonary TB, the most common form of the disease.
"A new, more effective TB vaccine would be game-changing in international efforts to eliminate TB globally by 2050," said Jim Connolly, President and Chief Executive Officer of Aeras. "Studies have already shown that this promising vaccine has an acceptable safety profile and stimulates strong immune responses in HIV-infected individuals."
Aeras is the trial sponsor, and significant funding is provided by EDCTP, a pan-European body that supports multicenter projects which combine clinical trials, capacity building and networking. This study has been approved by t
|Contact: Annmarie Leadman|